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Novel Biomarkers for Predicting
Preeclampsia
David M. Carty, Christian Delles, and Anna F. Dominiczak⁎
Preeclampsia is a major cause of maternal morbidity and mortality
worldwide. Despite decades of research into the condition, the ability of
clinicians to predict preeclampsia prior to the onset of symptoms has not
improved significantly. In this review, we will examine the pathophysiol-
ogy underlying preeclampsia and will look at potential biomarkers for
early prediction and diagnosis. In addition, we will explore potential
future areas of research into the condition. (Trends Cardiovasc Med
2008;18:186–194) n 2008, Elsevier Inc.
 Introduction
Preeclampsia is a multisystem disorder
of pregnancy, which complicates 3%-5%
of pregnancies in the western world. It is
a major cause of maternal morbidity and
mortality worldwide. The cardinal clin-
ical features of the condition are hyper-
tension and proteinuria occurring after
20 weeks gestation in women who were
not previously known to be hypertensive.
Other signs and symptoms include
edema and headache, and in severe
cases, the condition is associated with
seizures (eclampsia), liver, and kidney
dysfunction as well as clotting abnorm-
alities, Adult Respiratory Distress Syn-
drome and fetal growth restriction (FGR)
(Davison et al. 2004).
The cause of preeclampsia remains
unknown, and the only known cure is
delivery of the fetus and placenta.
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Various agents have been evaluated to
see whether they influence the develop-
ment of preeclampsia. Aspirin has been
studied extensively; it was summarized
in a Cochrane review by Duley et al.
(2004) to have modest but significant
benefits in preventing preeclampsia. It is
commonly used in women who are
known on the basis of risk factors to be
at high risk of developing preeclampsia,
although questions remain over exactly
which subgroups of women are most
likely to benefit. Studies of calcium
supplementation suggest that it is of
most benefit when used in high-risk
women with low dietary calcium intake
(Hofmeyr et al. 2006), although studies of
antioxidants such as vitamins C and E
and magnesium and zinc supplements
have been less promising (Poston et al.
2006).
Despite decades of research into the
condition, predicting which women are at
increased risk of developing preeclampsia
remains problematic. Identifying “at-risk”
women is an important aim; because
modern obstetric care places emphasis
upon the primary care setting for expec-
tant women, a marker which identified
high-risk women would allow for closer
supervision in secondary care. Such a
marker would also facilitate recruitment
for trials of potential therapeutic agents,
for accurate diagnosis, and for timely
intervention whenever problems develop.
Furthermore, predicting preeclampsia in
women with underlying conditions such
as diabetes and chronic hypertension
would be of great clinical value.
Clinicians have traditionally relied on
maternal risk factors, such as increased
maternal age, family history, and preex-
isting diseases, for determining which
women are at increased risk. The pro-
blem with using these risk factors is that
millions of women worldwide have these
risk factors but do not develop pree-
clampsia. Moreover, the majority of
them are nonmodifiable. There have
been many screening tests evaluated in
the literature over the years for predict-
ing preeclampsia; these have been com-
prehensively reviewed in a World Health
Organization publication (Conde-Agu-
delo et al. 2004) (Figure 1). A further
summary of predictive tests, including a
review of preventative interventions and
economic modeling, has been recently
published by the UK National Institute
for Health Research (Meads et al. 2008).
The imaging technique that has so far
been most widely used for predicting
preeclampsia has been uteroplacental
Doppler ultrasound. Impaired placental
perfusion, one of the hallmarks of pre-
eclampsia, can be assessed by measuring
flow waveform ratios or by detecting
diastolic notching of the uterine arcuate
vessels. Uterine Doppler studies can,
however, be inconsistent: different types
of machine, different gestational age at
assessment, and different definitions of
abnormal flow velocity waveforms make
accurate comparison of studies difficult.
A large systematic review of 43 studies
involving 40,000 patients (Conde-Agu-
delo et al. 2004) found that, in both low-
and high-risk patient groups, the positive
predictive value was not sufficiently high
to recommend routine screening.
Attention has therefore turned in
recent years towards identifying mater-
nal markers of placental dysfunction
which are raised in women who go on
to develop preeclampsia. In this review,
we will look at novel biomarkers which
have been used in the prediction of
preeclampsia and explore potential
future areas of investigation.
 Pathogenesis of preeclampsia
Although the cause of preeclampsia
remains elusive, the origin of the condi-
tion is recognized as lying in the placenta.
This is known to be the case because
preeclampsia occurs only in the presence
of pregnancy, it resolves after delivery of
the placenta and it can occur in the
absence of a viable fetus, for example, in
molar pregnancies. Placental develop-
ment is a closely regulated process which
is essential for normal fetal development
and for maintaining a successful preg-
nancy. Blood supply to the placenta is via
the spiral arteries, which, in turn, are
branches of the uterine arteries. Early in
normal pregnancy, the cytotrophoblastic
cells of the developing placenta invade the
uterine wall, disrupting the endothelium
and tunicamediaof the spiral arteries. The
vascular wall of the spiral arteries is
remodeled; this, in turn, leads to a trans-
formation of the spiral arteries from low-
flow, highly resistant vessels into the high-
flow, low-resistance vesselswhich are vital
for normal placental development.
There are thought to be two stages to
cytotrophoblastic invasion: the first
involves invasion of the decidual seg-
ments of the spiral arteries, at around 10-
12 weeks gestation; the second involves
invasion of the myometrial segments at
15-16 weeks (Sargent and Smarason
1995). In preeclampsia, the cytotropho-
blastic invasion of the myometrial seg-
ments is impaired: the spiral arteries
remain narrow, and blood supply to the
fetus is restricted. The effects of this on
the fetus become more significant as
pregnancy progresses, since the uterine
vasculature is unable to keep up with the
increased amount of blood and nutrients
necessary for fetal development. Placen-
tal ischemia is thought to develop as a
result of this abnormal cytotrophoblastic
invasion; this has been proposed as
leading to release of placental factors
and imbalance of angiogenic factors,
causing the widespread endothelial dys-
function which characterizes preeclamp-
sia (Lee et al. 2007).
 Angiogenic factors
As research in the field of preeclampsia
progresses, much of the attention in
recent years has been focused on peptides
related to angiogenesis. Angiogenesis, the
development of new blood vessels from
existing endothelium, is essential for
normal placental development. Two of
the angiogenic growth factors, vascular
endothelial growth factor (VEGF) and
placental growth factor (PlGF) are
thought to contribute to normal tropho-
blastic proliferation and implantation
(Thadhani et al. 2004), and it has been
hypothesized that an imbalance in levels
of these growth factors has a crucial role
in preeclampsia. As normal pregnancy
progresses, maternal VEGF expression is
reduced (Ong et al. 2000a), but placental
levels of mRNA-encoding VEGF have
been shown to be much lower in women
with preeclampsia compared to controls
(Cooper et al. 1996). Similarly, maternal
plasma levels of PlGF have been shown to
be significantly reduced in the second
trimester in women who went on to
develop preeclampsia compared to con-
trols (Kim et al. 2007). The use of anti-
VEGF antibodies for systemic treatment
in cancer has shown a dose dependant
association with hypertension and pro-
teinuria (Ostendorf et al. 2007), which
may indicate that these factors have a role
in the development of preeclampsia.
Many recent studies have therefore con-
centrated on factors which antagonize
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VEGF and PlGF to assess their role in the
development of preeclampsia. Two of the
most extensively studied peptides, which
are produced by the placenta, are soluble
FMS-like tyrosine kinase (sFLT-1) and
soluble endoglin.
 Soluble sFLT-1
Soluble FLT-1 (also known as soluble
VEGF receptor 1 or sFLT-1) is a secreted
splice variant of FLT-1. It binds to and
neutralizes the angiogenic actions of
VEGF and PlGF (Venkatesha et al. 2006)
and is thought to be one of the key
peptides involved in the development of
preeclampsia. Maternal serum levels of
sFLT-1 have been shown to be elevated in
women with preeclampsia compared to
controls (Koga et al. 2003, Salahuddin et
al. 2007, Chaiworapongsa et al. 2004), to
correlate with disease severity (Chaiwor-
apongsa et al. 2004) and to decrease
markedly following delivery (Koga et al.
2003). It has also been shown that that
levels of sFLT-1 are increased in nullipar-
ity (one of themain known risk factors for
developing preeclampsia) when com-
pared to multiparous women (Wolf et al.
2005). A series of studies by Maynard et
al. (2003) revealed that mRNA of sFLT-1
is up-regulated in the placenta of women
with preeclampsia, leading to increased
systemic levels. Furthermore, these
authors demonstrated that when a
recombinant adenovirus encoding sFLT-
1 was injected into pregnant rats, hyper-
tension and proteinuria, as well as glo-
merular endotheliosis, one of the typical
pathological lesions seen in preeclamp-
sia, were observed. Further evidence for
the placental origin of the elevated sFLT-1
was provided by Staff et al. (2005). Given
that “delivery” includes both the fetus and
the placenta, the group investigated
whether fetal as well as maternal levels
of sFLT-1 were elevated in preeclampsia.
They found that although fetal levels of
sFLT-1 (measured in cord blood) are
elevated in preeclampsia, the maternal
serum levels were 29-fold higher and
concluded that there was no substantial
fetal contribution to the elevated circulat-
ing maternal sFLT-1 levels seen in pre-
eclampsia. Finally, serum sFLT-1 levels
have been shown to be increased in
women with preeclampsia superimposed
upon systemic lupus erythematosis (Qazi
et al. 2008) and glomerulonephritis
(Masuyama et al. 2006).
 Soluble Endoglin
Another peptide that has been implicated
in the pathogenesis of preeclampsia is
soluble endoglin (sEng). Endoglin, a
coreceptor for transforming growth fac-
tors β1 and β3 (Luft 2006), is highly
expressed on endothelial cell membranes
and syncytiotrophoblasts. Mutations in
the gene encoding Eng are the under-
lying cause of hereditary haemorrhagic
telangiectasia, a genetic condition char-
acterized by atrioventricular malforma-
tions, epistaxis, and telangiectasiae
(Venkatesha et al. 2006). In normal
pregnancy, levels of sEng fall between
the first and second trimesters, but in
women who go on to develop preeclamp-
sia, this reduction is blunted (Rana et al.
2007). Consistent with studies involving
sFLT-1, it has also been demonstrated
that levels of sEng are elevated in the
sera of pregnant women with preeclamp-
sia, correlate with disease severity, and
fall after delivery (Venkatesha et al.
2006). A promising discovery in terms
of predicting the condition was that
levels of sEng are elevated several
weeks before the development of clinical
symptoms in women who developed
preeclampsia; furthermore, in patients
who developed preterm preeclampsia,
the serum sEng levels are elevated
(approximately twofold) as early as
gestational weeks 17-20 (Levine et al.
2006). Rana et al. (2007) found that
although levels of sEng and sFLT-1
were found to be elevated in the serum
of preeclamptic women at 17-20 weeks
gestation when compared to controls,
the levels at 11-13 weeks were similar
between cases and controls. Both sEng
and sFLT-1 appear, therefore, to be
important peptides in the pathogenesis
of preeclampsia although, when used
alone, do not appear to have a suffi-
ciently high positive predictive value to
be translated into routine clinical practice.
 Placental Protein 13
Placental protein 13 (PP-13) is a 32-kDa
dimer protein, one of a group of proteins
which are known to be highly expressed
in the placenta. It has been prepared in
recombinant form and is thought to be
involved in placental implantation and
maternal vascular remodeling (Nico-
laides et al. 2006). During normal preg-
nancy, levels of PP-13 gradually increase,
but abnormally low levels of PP-13 have
been shown in weeks 11-13 gestation in
women who went on to develop pree-
clampsia and FGR when compared with
controls (Burger et al. 2004). A further
study, analyzing maternal serum PP-13
levels at 9-12 weeks gestation, also found
lower levels in women who went on to
develop preeclampsia compared with
controls (Chafetz et al. 2007). Combining
maternal serum PP-13 to uterine artery
Doppler studies early in pregnancy seems
to improve ability to predict severe
preeclampsia. Nicolaides et al. (2006)
found that women who went on to
develop preterm preeclampsia (requiring
delivery before 34 weeks) had a higher
median uterine artery pulsatility index,
and a lower median serum PP-13 in the
first trimester when compared to con-
trols. Thus, they concluded that, for a
90% detection rate of the condition,
using serum PP-13 for all women and
Doppler studies in the 14% at highest
risk, a false-positive rate of 6% could be
achieved. PP-13, therefore, whether used
alone or in combination with Doppler
studies, appears to be a promising area
for future research in this field.
 Pregnancy-Associated Plasma
Protein A
Pregnancy-associated plasma protein A,
(PAPP-A) is a large highly glycosylated
protein complex produced by the devel-
oping trophoblast (Bersinger et al. 2003),
which is used in many centers as a
marker for Downs' syndrome. It has
been shown to be responsible for the
cleavage of insulin-like growth factor
(IGF) binding proteins, which are inhibi-
tors of IGF action, in several biological
fluids (Laursen et al. 2001). PAPP-A was
first shown to be elevated in the plasma of
preeclamptic women nearly 30 years ago
(Hughes et al. 1980). More recent studies
have shown that although reduced first
trimester serum levels of PAPP-A are
associated with preeclampsia, levels are
also low in other complications of preg-
nancy (Ong et al. 2000b, Yaron et al. 2002,
Smith et al. 2002). It has been suggested
that PAPP-A is more useful as amarker of
FGR than of preeclampsia (Canini et al.
2008). In a recent paper, Spencer et al.
(2008) described a small increase in
likelihood ratio of developing preeclamp-
sia with decreasing levels of PAPP-A.
Although PAPP-A alone was not a good
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predictor for preeclampsia, they felt,
similarly to PP-13, that sensitivity could
be improved by combining with uterine
artery Doppler studies.
 Insulin Resistance
Insulin resistance has long been impli-
cated in the pathogenesis of preeclamp-
sia. Carbohydrate metabolism is known
to be altered in women with preeclamp-
sia, whereas fasting insulin levels have
also been shown to be elevated prior to
the onset of disease (Spencer et al.
2005). Furthermore, types 1 and 2
diabetes, gestational diabetes, and poly-
cystic ovarian syndrome are all well-
established risk factors for the condition
(Wolf et al. 2002).
Normal pregnancy is characterized by
increased insulin secretion by the pan-
creatic β cells, and, following initially
increased insulin sensitivity, there fol-
lows a progressive increase in insulin
resistance throughout the second and
third trimesters (Butte 2000). Sex-hor-
mone-binding globulin (SHBG) is a
glycoprotein produced by the liver
which binds circulating estrogens and
testosterone. Production of SHBG is
inhibited by insulin; therefore, low levels
of SHBG are associated with elevated
insulin levels. As a result, studies have
used low SHBG levels as a marker of
insulin resistance in both cardiovascular
disease (Sherif et al. 1998) and in
preeclampsia (Carlsen et al. 2005, Spen-
cer et al. 2005, Wolf et al. 2002). One
study looking at first-trimester SHBG
levels in 45 nulliparous women who
developed preeclampsia found that levels
were significantly reduced when com-
pared with controls (Wolf et al. 2002). In
contrast, however, a further study look-
ing at SHBG levels at weeks 10-14 in 107
women with preeclampsia found no
significant difference between women
who went on to develop preeclampsia
compared to controls (Spencer et al.
2005). This retrospective study included
multiparous women, which may have
confounded results. Another study found
no difference at gestational weeks 17 or
33 between 29 cases of preeclampsia and
controls (Carlsen et al. 2005), although
the relatively small numbers of patients
involved may be of relevance.
Adiponectin, an adipocyte-derived
cytokine involved in carbohydrate and
fat metabolism, is another protein whose
levels are inversely correlated with insu-
lin resistance. High concentrations of
adiponectin have been shown to be
protective against the development of
type 2 diabetes (Lindsay et al. 2002),
and serum levels of adiponectin have
Figure 1. Biomarkers of pre-eclampsia. Biomarkers of preeclampsia are grouped into four major categories (modified from Conde-Agudelo et al.
2004). Production and levels of biomarkers are ultimately dependent on genetic factors and therefore genomic studies are likely to detect genetic
variants associated with preeclampsia. However, in contrast to the static genome, the proteome is dynamic. Whereas the genome will not change
during pregnancy or pregnancy-associated conditions such as preeclampsia, the proteome will change. This is indicated by the double-headed
arrow. Proteomic and metabolomic studies will therefore reflect a large number of biomarkers and their actual levels and will more accurately
predict risk than genomic studies.
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been shown to correlate with sEng levels
in womenwith preeclampsia (Masuyama
et al. 2007). It has been hypothesized that
low serum adiponectin levels are asso-
ciated with an increased risk of develop-
ment of preeclampsia. D'Anna et al.
(2006) examined serum adiponectin
levels in the first trimester in women
who subsequently developed preeclamp-
sia. They found that levels were lower
than those in controls, but the levels were
significantly different between those who
developed early-onset and late-onset
symptoms, suggesting a different patho-
genesis. Ramsay et al. (2003) found, in
contrast to their initial hypothesis, that
serum adiponectin levels in the third
trimester are in fact higher in women
with preeclampsia compared with con-
trols, a finding which has been con-
firmed elsewhere (Fasshauer et al.
2008). It has been suggested that adipo-
nectin forms part of the physiological
response to preeclampsia, by improving
insulin sensitivity (Fasshauer et al. 2008).
It appears, therefore, that although insu-
lin resistance has a prominent role in
the pathogenesis of preeclampsia, its
role in predicting the disease, and the
best method for measuring it, are yet to
be determined.
 Apolipoprotein E
One of the mechanisms by which pre-
eclampsia has been postulated to develop
is via abnormal lipid metabolism asso-
ciated with oxidative stress. Women with
preeclampsia have an abnormal lipid
profile, with elevated concentrations of
triglyceride-rich lipoproteins, which may
contribute to endothelial dysfunction
(Sattar et al. 1997). Apolipoprotein E
(ApoE) is a major constituent of very
low-density lipoproteins (VLDLs) whose
role involves modifying inflammatory
responses, and removal of excess choles-
terol from the circulation via regulation
of hepatic uptake (Belo et al 2004). The
APOE gene on chromosome 19 has 3
common alleles, encoding 3 plasma
ApoE isoforms, e2, e3, and e4. ApoE e4
is a known risk factor for familial
Alzheimer's disease, whereas both e2
and e4 isoforms have been associated
with abnormally high triglyceride and
VLDL levels (Francoual et al. 2002). It
has been postulated that ApoE levels and
polymorphisms of its gene are associated
with an increased risk of preeclampsia.
Nagy et al. (1998), found a higher
incidence of the ApoE e2 allele amongst
women with preeclampsia compared to
controls. Makkonen et al. (2001) studied
133 women with preeclampsia and, in
contrast, found that none of the ApoE
alleles were over represented when com-
pared with controls, findings that have
been confirmed elsewhere (Belo et al.
2004). The role of this avenue of investi-
gation in the prediction of preeclampsia
is therefore, at present, uncertain.
 Inhibin A and Activin A
Many studies have been reported using
inhibin A and activin A as predictors of
preeclampsia. Both are glycoproteins,
are members of the transforming
growth factor β family, and during
pregnancy, are largely released by the
fetoplacental unit. Inhibin A has an
important endocrine role in the negative
feedback of gonadotrophins, whereas
activin A is thought to have activity in
various biological tissues (Luisi et al.
2005, Muttukrishna et al. 2000). In
normal pregnancy, concentrations of
both hormones rise in the third trime-
ster, and levels have been shown to be
elevated approximately 10-fold in
women with severe preeclampsia com-
pared to controls (Muttukrishna et al.
1997). Second trimester levels of inhibin
A have been shown to be elevated in
Figure 2. Capillary electrophoresis online coupled to mass spectrometry. Urine samples are
prepared for analysis, polypeptides are separated by capillary electrophoresis and directly
sprayed into electrospray ionization–time of flight mass spectrometry. Data are evaluated using
specific software solutions. Each polypeptide is defined by its accurate mass and normalized CE
migration time. Signal intensity serves as measure of the relative abundance. The data are
stored as peak lists summarizing the information in a database. The process is demonstrated for
use of CE–mass spectrometry to in the diagnosis of coronary artery disease. The lower panel
shows a coronary artery disease-specific polypeptide pattern. The top panel is modified with
permission from Electrophoresis 2007;28:1407-1417. Sniehotta et al: CE - a multifunctional
application for clinical diagnosis. Electrophoresis. 2007. Volume 28. Pages 1407-1417.
Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission.
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both serum (Aquilina et al. 1999) and
amniotic fluid (Kim et al. 2006) in
women who went on to develop severe
preeclampsia, and when measured at
term, serum levels have been shown to
correlate with preeclampsia severity
(Zeeman et al. 2002). Interestingly,
urinary activin A and inhibin A levels
have also been found to be elevated in
women with preeclampsia, as have
uterine vein levels (Muttukrishna et al.
2006). The second trimester levels of
both inhibin A and activin A have been
reported to add significant prognostic
information when measured in women
with abnormal uterine artery Doppler
studies (Florio et al. 2003). In contrast
to the above, however, a study by
Davidson et al. (2003) found that
although second trimester levels of
activin A were elevated in women who
went on to develop preeclampsia, inhi-
bin A levels were not elevated, findings
confirmed by D'Anna et al. (2002).
Studies using first trimester inhibin A
(Roes et al. 2004) have also shown a low
predictive value.
The cause of these rises in activin A
and inhibin A is not yet fully understood;
and whether these hormones have a role
in the etiology of preeclampsia is not yet
known. Further prospective studies,
including measurement of urinary inhi-
bin A, are clearly required.
 Genomics and Proteomics
A number of gene polymorphisms have
been found to be associated with the
risk of developing preeclampsia. A
recent well-powered study into the
genetics of preeclampsia, however, did
not confirm significant associations
between a single nucleotide polymorph-
isms in candidate genes and preeclamp-
sia (GOPEC Consortium 2005). Recent
advances in genotyping technology will
facilitate genome-wide association stu-
dies in preeclampsia which will very
likely result in novel candidate genes for
the disorder. Results from studies into
other polygenic disorders such as cor-
onary artery disease and diabetes are
promising (Wellcome Trust Case Con-
trol Consortium 2007), but investigators
will have to follow strict rules to avoid
false positive and underpowered nega-
tive results (NCI-NHGRI Working
Group on Replication in Association
Studies 2007).
Further advances are expected from
proteomic research. Proteomics has been
defined as “knowledge of the structure,
function, and expression of all proteins in
the biochemical or biological contexts of
all organisms” (Kenyon et al. 2002).
Comparing protein patterns between
healthy patients and those with a disease
has been increasingly used in recent
years to discover markers of disease
(biomarkers), which have a number of
important roles in medical research.
Proteomics can be used to improve
early detection of disease, to develop
new targets for therapeutic treatment,
and to monitor response to treatment
(Figure 1). To date, potential proteomic
biomarkers have been reported for early
diagnosis of cardiovascular disease
(Zimmerli et al. 2008), renal transplant
rejection (Wittke et al. 2005), urological
cancers (Saito et al. 2005), and acute
kidney injury (Zhou et al. 2006). Human
urine is an ideal medium to study
proteomics because of its ease of collec-
tion, and its relative stability. Normal
human urine contains up to 150 mg of
protein/24 hours and contains much
useful information about the kidneys
and urogenital tract; because urine is a
filtrate of blood, pathological changes in
the blood indicative of disease can be
reflected in the urinary proteome (Gon-
zalez-Buitrago et al. 2007). Proteomics
employs protein separation using two-
dimensional gel electrophoresis, high-
performance liquid chromatography, or
capillary electrophoresis (CE), coupled
online to a time-of-flight mass spectro-
meter (Figure 2). This allows the mole-
cular weight of a single molecule to be
measured and displayed according to its
mass: charge ratio. Each peptide has a
molecular “fingerprint,” and this tech-
nology allows simultaneous examination
of several thousand peptides within
minutes. Once a biomarker “signature
profile” has been identified, it can be
compared with healthy closely matched
controls, allowing for a disease-specific
biomarker to be identified.
It appears likely that the development
of preeclampsia involves several different
pathophysiological mechanisms, as evi-
denced by the diversity of the peptides
that have been studied to date. Current
research is driven by pathways that are
known to be involved in the development
of the condition, and one advantage of
proteomics-based research is that many
of these mechanisms can be integrated.
In addition, since proteomics is a
“hypothesis-free” research tool, it is likely
that this line of investigation will open
new avenues for potential biomarker
discovery and for new diagnostic and
preventative measures.
 Metabolomics
Metabolomics is a further area that has
the potential to contribute significantly
to future research in preeclampsia. In
complement to studies examining the
human genome and proteome, metabo-
lomics can be defined as a “systematic
study of the unique chemical finger-
prints that specific cellular processes
leave behind” (Daviss 2005). In common
with proteomics, studies of the human
metabolome can be carried out on
routine samples of urine, plasma, or
serum requiring minimal specialist pre-
paration of samples. Metabolomics (also
referred to as metanomics or metabo-
nomics) has been used to characterize
signature profiles for cardiovascular
disease (Brindle et al. 2002), for Alzhei-
mer's disease (Han et al. 2002), and for
hypertension (Brindle et al. 2003). A
study evaluating the ability of metabo-
lomics in diagnosis of preeclampsia has
been reported (Kenny et al. 2005). They
discovered three metabolomic peaks
which could be used with high sensitiv-
ity and specificity to differentiate
women with preeclampsia from con-
trols. In this study, the majority of
samples were taken in late pregnancy,
and so, the ability of these metabolomic
peaks to predict preeclampsia before the
onset of clinical disease remains uncer-
tain. Although the group were, at that
point, unable to identify the metabolites
involved, it is likely that future research
in this field will aid our understanding
of this challenging condition.
 Conclusion
Although improvements in obstetric and
neonatal care have led to a reduction in
morbidity and mortality from pree-
clampsia, our ability to predict the con-
dition has not improved significantly. We
currently rely on “secondary prevention”
of preeclampsia: women who have pre-
viously had the disease are closely mon-
itored throughout pregnancy. The
majority of women who develop
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preeclampsia, however, are only diag-
nosed once they have developed the full-
blown manifestations of the condition,
by which time treatment options are
limited. Rather than being a separate
condition, preeclampsia has been pre-
viously described as the extreme end of a
maternal systemic response engendered
by pregnancy itself (Redman and Sargent
2003). We have seen that many of the
proposed biomarkers for preeclampsia
are raised to a lesser extent in normal
pregnancy, which will make discovery of
accurate biomarkers for preeclampsia
more difficult. Nevertheless, if signs of
abnormal placental and endothelial dys-
function could be detected prior to the
onset of clinical disease, they would
represent an extremely attractive target
for emerging therapeutic strategies. In
addition, any such treatments would be
most likely to be effective if they could be
started in early gestation. In routine
clinical practice, we currently screen for
several conditions in early pregnancy,
most of which have a far lower incidence
than preeclampsia, and it is hoped that
in time we will be able to do the same
for preeclampsia.
An increased understanding of the
molecular mechanisms underlying pre-
eclampsia has led to several potential
areas of investigation. In addition to
studies mentioned above, novel biomar-
kers such as urine orosomucoid, an acute
phase protein, show promise in early
prediction of preeclampsia (Kronborg et
al. 2007). To date, however, studies of
potential biomarkers for predicting pre-
eclampsia have involved relatively small
numbers of patients, although many of
the studies have ambiguous definitions of
preeclampsia and unclear distinction of
early and severe disease. It is unlikely that
a single marker will prove to be an
accurate predictive tool for preeclampsia;
a combination of clinical information
regarding history and risk factors along
with urine or blood biomarkers in those
at risk is more realistic. There is clearly a
great need for development of predictive
tools for preeclampsia; it is hoped that
proteomics, metabolomics, and other
techniques will allow us to develop
biomarkers with high enough predictive
and prognostic information to be trans-
lated into clinical practice. These devel-
opments could well be the key to
improving care for women with this
devastating condition.
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Of Cardiovascular Illness and Diversity
of Biological Response
Pascal J. Goldschmidt-Clermont⁎, Chunming Dong,
Mike West, and David M. Seo
Noise in gene expression (stochastic variation in the composition of the
transcriptome in response to stimuli) may play an important role in
maintaining robustness and flexibility, which ensure the stability of
normal physiology and provide adaptability to environmental changes
for the living system. Broad-based technologies have allowed us to study
with unprecedented accuracy the molecular profiles of various states of
health and cardiovascular disease. In doing so, we have observed a
correlation between the degree of variation in gene expression and the
state of health. Specifically, the stochastic variation in gene expression
in response to environmental and physiological factors is found in
healthy mice, and tends to disappear in mice with advanced disease
states. Although further evidence is needed to draw a solid conclusion
with respect to the significance of decreased transcriptional noise in the
disease state as a whole, it is tantalizing to introduce the concept that
stochasticity may be linked to the organism's adaptability to a changing
environment, and the “quiet” states of gene expression may indicate the
loss of diversity in the organism's response. (Trends Cardiovasc Med
2008;18:194–197) n 2008, Elsevier Inc.
 Noise in Gene Expression—
A Requisite for Health?
Over the past couple of years, substantial
progress has been made in the identifica-
tion of genetic sources underlying
expression differences between indivi-
dual cells and organisms (Raser and
O'Shea 2005). The differences (noise) in
gene expression refer to the stochastic
variation in gene expression among cells
and organisms within a homogeneous
population in common environment. The
potential sources for such a variation
include (1) inherent stochasticity of
biochemical processes involving infre-
quent molecular events concerning
small numbers of molecules; (2) differ-
ences in the internal states of a popula-
tion of cells and organisms, such as
chromatin modification (epigenetics);
(3) subtle environment differences, such
as morphogen gradients in multicellular
development (such as regulatory small
RNA molecules); (4) ongoing genetic
mutation; and (5) topology of gene
regulatory networks, such as presence
and absence of functional feedback
loops. Although fluctuations in gene
expression as a result of intrinsic noise
could be detrimental to cellular and
organismal physiology, they have been
found to be beneficial in many circum-
stances. Indeed, noise has been shown to
provide a mechanism for single cell
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